Splenomegaly as a primary manifestation of Gaucher disease in a young adult woman
- PMID: 21897802
- PMCID: PMC3166814
- DOI: 10.1159/000178329
Splenomegaly as a primary manifestation of Gaucher disease in a young adult woman
Abstract
Gaucher disease is the most common lysosomal storage disease. It is caused by the defective activity of acid β-glucosidase, which results in the accumulation of lipid glucocerebroside in macrophages throughout the body. In this case report we describe the case of a young adult woman with splenomegaly as the primary manifestation of this pathology. This is a case of type 1 Gaucher disease because there is a lack of primary neurological involvement but we have, instead, an age-independent involvement of the visceral organs. It is very important to classify or characterize these patients in a precise manner and to make a complete diagnosis with the help of the many diagnostic resources now at our disposal, especially with genetics, radiology and new techniques of advanced microscopy, also because Gaucher disease requires a long and complex management from early life to adulthood.
Keywords: Accumulation; Gaucher disease; Lysosomal storage disease; Macrophages; Splenomegaly.
Similar articles
-
Biochemical and molecular characterization of adult patients with type I Gaucher disease and carrier frequency analysis of Leu444Pro - a common Gaucher disease mutation in India.BMC Med Genet. 2018 Oct 1;19(1):178. doi: 10.1186/s12881-018-0687-5. BMC Med Genet. 2018. PMID: 30285649 Free PMC article.
-
Case report: Multidisciplinary collaboration in diagnosis and treatment of child gaucher disease.Front Pediatr. 2023 Mar 30;11:1057574. doi: 10.3389/fped.2023.1057574. eCollection 2023. Front Pediatr. 2023. PMID: 37063666 Free PMC article.
-
Gaucher Disease: One of the Few Causes of Massive Splenomegaly.Eur J Case Rep Intern Med. 2022 Dec 19;9(12):003705. doi: 10.12890/2022_003705. eCollection 2022. Eur J Case Rep Intern Med. 2022. PMID: 36632535 Free PMC article.
-
Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.Curr Opin Investig Drugs. 2010 Oct;11(10):1169-81. Curr Opin Investig Drugs. 2010. PMID: 20872320 Review.
-
Gaucher disease: from fundamental research to effective therapeutic interventions.Neth J Med. 2003 Jan;61(1):3-8. Neth J Med. 2003. PMID: 12688562 Review.
Cited by
-
A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach.Int J Biol Sci. 2024 Mar 17;20(6):2111-2129. doi: 10.7150/ijbs.87741. eCollection 2024. Int J Biol Sci. 2024. PMID: 38617529 Free PMC article. Review.
References
-
- Butters TD. Gaucher disease. Curr Opin Chem Biol. 2007;11:412–418. - PubMed
-
- Schmitz J, Poll LW, von Dahl S. Therapy of adult Gaucher disease. Haematologica. 2007;92:148–152. - PubMed
-
- Mignot C, Doummar D, Maire I, et al. French Type 2 Gaucher Disease Study Group Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev. 2006;28:39–48. - PubMed
-
- Grabowski GA. Recent clinical progress in Gaucher disease. Curr Opin Pediatr. 2005;17:519–524. - PubMed
-
- Lutsky KF, Tejwani NC. Orthopaedic manifestations of Gaucher disease. Bull NYU Hosp Jt Dis. 2007;65:37–42. - PubMed
Publication types
LinkOut - more resources
Full Text Sources